(688136)"SHAN DONG KEXING BIOPRODUCTS CO., LTD."Report for Q3 2026
Filed with SSE · Stock code 688136 · · 13 pages · Chinese
Summary by 6ix AI
The report indicates a significant decline in revenue and net profit compared to the same period last year, attributed to factors such as changes in tax rates and market conditions. The company continues to invest heavily in research and development, with a notable increase in R&D expenses as a percentage of revenue. Additionally, Kexing Biopharm is advancing its clinical pipelines and expanding its international market presence with new product approvals.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Kexing Biopharm Co., Ltd. on 6ix
Earlier from Kexing Biopharm
- New Opportunities for Global Cooperation: Kexing Biopharm Shines at CPHI Milan 2026
- (688136)"SHAN DONG KEXING BIOPRODUCTS CO., LTD."Announcement on Voluntary Disclosure of Acceptance of Marketing Authorization Application for Pegylated Human Granulocyte Colony-Stimulating Factor Injection
- Kexing Biopharm's Investigational Anti-TL1A Monoclonal Antibody GB20 Cleared for Clinical Trials in China
- SHAN DONG KEXING BIOPRODUCTS CO., LTD.: Announcement on Voluntary Disclosure of Receipt of the Clinical Trial Approval Notice for GB20 Injection
- SHAN DONG KEXING BIOPRODUCTS CO., LTD.: Announcement on Participating in the 2026 Semi-annual Collective Performance Briefing for the STAR Market Innovative Drug Industry
Follow Kexing Biopharm into a list and get an email when it puts out news.
Follow Kexing Biopharm